A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women
This article, published in the New England Journal of Medicine, reports on a study to determine the efficacy and immunogenicity of an investigational 9-valent human papillomavirus (HPV) vaccine in women 16 to 26 years of age. The authors found that the 9-valent vaccine prevented infection and disease related to HPV-31, 33, 45, 52, and 58 and generated an antibody response to HPV-6, 11, 16, and 18 that was noninferior to those generated by the existing quadrivalent HPV vaccine. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Joura EA, Giuliano AR, Iversen O-E, et al.
» Visit web page (English)
(Located at www.nejm.org)
Citation: Joura EA, Giuliano AR, Iversen O-E, et al. A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine. 2015;372(8):711-723.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)